Standardization of the components of niprisan: A phytomedicine for treating sickle cell disease

Journal of Medicinal Plants Research

Volumn 3, Issue 4, 2009, Pages 284-289

  Obodozie, O O ^a   Ameh, S J ^a   Afolabi, E K ^a   Oyedele, E O ^a   Ache, T A ^a   Onanuga, C E ^a   Ibe, M C ^a   Inyang, U S ^a  

^a NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (Nigeria)

Author keywords

Components; Niprisan; Phytomedicine; Sickle cell disease; Specifications; Standardization

Indexed keywords

MINERAL; NIPRISAN; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; TRONA; UNCLASSIFIED DRUG;

ARTICLE; BUD; CALCULATION; CHEMICAL COMPOSITION; CLOVE; DRUG QUALITY; FOREIGN MATTER CONTENT; LOSS ON DRYING; MEDICINAL PLANT; NONHUMAN; PARAMETER; PETIOLE; PIPER GUINEENSE; PLANT SEED; PLANT STEM; PTEROCARPUS OSUN; QUALITY CONTROL; SICKLE CELL ANEMIA; SORGHUM BICOLOR; STANDARDIZATION; TECHNIQUE; TOTAL ASH; WATER EXTRACTABLE MATTER;

PIPER GUINEENSE; PTEROCARPUS OSUN; SORGHUM BICOLOR; SYZYGIUM AROMATICUM; TRONA;

EID: 73449140824     PISSN: 19960875     EISSN: 19960875     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Akunyili D (2002). Herbal Preparations. NAFDAC Consum. Saf. Bull. 1(2): 5-6.
2. Awodogan AA, Wambebe C, Gamaniel K, Okogun J, Orisadipe A, Akah P (1996). Acute and Short-term Toxicity of NIPRISAN® in Rats I: Biochemical Study. J. Pharm. Res Dev. 2: 39-45.
3. British Pharmacopoeia (2004).The Stationery Office Limited, London. Appendix II D, Atomic spectrophotometry: emission and absorption, pp. A143-145. Determination of pH, pp. A143-145; Appendix VL, Determination of pH Values, pp. A199-A200.
4. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR(1995). Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia. New England J. Med. 332(20):1317-1322.
5. Cordeiro NJV, Oniyangi O (2006). Phytomedicines [medicines derived from plants] for sickle cell disease. The Cochrane Database of Systematic Review 2006 Issue 3.
6. Duke JA, Wain KK (1981). Medicinal plants of the world. Computer index with more than 85,000 entries. 3 vols.
7. Etkin NL (2006). Edible Medicines: An Ethnopharmacology of Food. Tucson: University of Arizona Press, September 30. pp. 87-88.
8. European Pharmacopoeia (2000). European Pharmacopoeia (Supplement 2000). Technical Secretariat of the European Pharmacopoeia Commission.
9. Gaedcke (2003). Definitions. In: Gaedcke, F. W., Steinhoff, S. K. and Blasius, H. R. [Eds.], Herbal Medicinal Products: Scientific and Regulatory Basis for Development, Quality Assurance and Marketing Authorization. Stuttgart: Medpharm Scientific Publishers, pp. 1-28.
10. Gamaniel K, Amos S, Akah P, Samuel B, Olusola A, Abayomi O, Okogun J, Wambebe C (1998). Pharmacological Profile of NIPRD 94/002/1-0: A Novel Herbal Antisickling Agent. J. Pharm. Res. Dev. 3:(2) 89-94.
11. th Annual Meeting of the National Sickle Cell disease Program, April 18-21, Los Angeles, California.
12. http://www.medscape.com/px/viewindex/more?Bucket=columns§ionId= 2557
13. Iyamu EW, Turner EA Asakawa T (2003). Niprisan [Nix-0699] improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br. J. Haematol. 122(6): 1001-1008.
14. Obodozie OO (2000). Standardization of Herbal Medicines. Being a Paper delivered at: Strategies to Strengthen the Utilization of Medicinal and Aromatic Plants in the National Health Care System. 11-13 July 2000. National Institute for Pharmaceutical Research and Development [NIPRD], Idu, Abuja, Nigeria.
15. Okore VC, Obimah DU (1998). Mechanism of the Laxative Actions of a Mineral Salt, Trona. . J. Pharm. Res. Dev. 3: (2) 72-74.
16. Pandey RC (2003). Xechem's Sickle Cell Drug, NIPRISAN -HEMOXIN-Granted Orphan Drug Status by the FDA NEW BRUNSWICK, N.J. - (BUSINESS WIRE) - Sept. 2, 2003 - Xechem International, Inc. (OTC BB: XKEM).
17. Piomelli, S (1992). Bone marrow transplantation in sickle cell diseases: a plea for a rational approach. Bone Marrow Transplant. 1992; 10: Suppl 1: 58-61.
18. Sofowora EA (1979). Isolation and characterization of an antisickling agent from the root of Fagara zanthoxyloides. In: Sofowora, A. and Sodeye, A. I. (Eds.), Fagara and the red blood cell. Proceedings of a symposium. University of Ife Press, Ile-Ife, Nigeria, pp. 79-87.
19. Steinberg MH (1999). Management of Sickle Cell Disease. N Engl J Med. 340 (13): 1021-1030.
20. Waknine Y (2005). Orphan Drug Niprisan (Nicosan/ Hemoxin) for Sickle Cell Disease in EU: The European Medicine Evaluation Agency has approved orphan drug status for the phytomedicine niprisan in the treatment of sickle cell disease. International Approvals. Oct. 25, 2005.
21. Wambebe C, Khamofu H, Momoh JA, Ekpeyong M, Audu BS, Njoku SO, Nasipuri N. R., Kunle O. O., Okogun, J. I., Enwerem, N. M., Gamaniel, S. K., Obodozie, O. O., Samuel, B., Fojule, G. and Ogunyale, P. O (2001). Double-blind, placebo-controlled, randomized cross-over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine 2001 Jul; 8(4):252-61.
22. WHO (1998). Quality control methods for medicinal plant materials. Geneva: WHO. pp. 1-115.